|
SIPA1L3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.89759999994033E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.97060000001792E-07 |
| Normal-vs-Stage2 |
9.564100E-03 |
| Normal-vs-Stage3 |
1.010420E-04 |
| Normal-vs-Stage4 |
4.15559999999981E-06 |
| Stage1-vs-Stage2 |
3.555600E-01 |
| Stage1-vs-Stage3 |
9.380800E-01 |
| Stage1-vs-Stage4 |
2.784600E-01 |
| Stage2-vs-Stage3 |
4.715000E-01 |
| Stage2-vs-Stage4 |
1.565810E-01 |
| Stage3-vs-Stage4 |
3.480800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.41239999998477E-06 |
| Normal-vs-AfricanAmerican |
1.883790E-01 |
| Normal-vs-Asian |
1.77199999995548E-06 |
| Caucasian-vs-AfricanAmerican |
9.062400E-02 |
| Caucasian-vs-Asian |
6.841600E-02 |
| AfricanAmerican-vs-Asian |
6.179500E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.063310E-03 |
| Normal-vs-Female |
1.52320999999844E-05 |
| Male-vs-Female |
2.269800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.5740799999997E-05 |
| Normal-vs-Age(41-60Yrs) |
3.52639999999793E-05 |
| Normal-vs-Age(61-80Yrs) |
3.53130000000368E-05 |
| Normal-vs-Age(81-100Yrs) |
6.627800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.022400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.993800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.738600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.356800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.502200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.274000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.046300E-02 |
| Classical-VS-Follicular |
2.027000E-01 |
| Classical-VS-Other |
8.129400E-01 |
| Classical-VS-Normal |
3.232700E-04 |
| Tall-VS-Follicular |
3.421600E-01 |
| Tall-VS-Other |
3.951600E-01 |
| Tall-VS-Normal |
3.87010000002519E-06 |
| Follicular-VS-Other |
8.356800E-01 |
| Follicular-VS-Normal |
7.559800000001E-05 |
| Other-VS-Normal |
9.590200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95745999999053E-05 |
| Normal-vs-N1 |
9.51420000006031E-07 |
| N0-vs-N1 |
1.167390E-01 |
|
|
